Literature DB >> 18706128

Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.

Arthur L Brody1, Mark A Mandelkern, Matthew R Costello, Anna L Abrams, David Scheibal, Judah Farahi, Edythe D London, Richard E Olmstead, Jed E Rose, Alexey G Mukhin.   

Abstract

Our group recently reported that smoking a regular cigarette (1.2-1.4 mg nicotine) resulted in 88% occupancy of brain alpha4beta2* nicotinic acetylcholine receptors (nAChRs). However, this study did not determine whether nicotine inhalation or the many other pharmacological and behavioural factors that occur during smoking resulted in this receptor occupancy. If nicotine is solely responsible for alpha4beta2* nAChR occupancy from smoking, then (as estimated from our previous data) smoking a denicotinized (0.05 mg nicotine) or a low-nicotine (0.6 mg nicotine) cigarette (commonly used for research and clinical purposes) would result in substantial 23% and 78% alpha4beta2* nAChR occupancies, respectively, and a plasma nicotine concentration of 0.87 ng/ml would result in 50% alpha4beta2* nAChR occupancy (EC50). Twenty-four positron emission tomography sessions were performed on tobacco-dependent smokers, using 2-[F-18]fluoro-A-85380 (2-FA), a radiotracer that binds to alpha4beta2* nAChRs. 2-FA displacement was determined from before to 3.1 hours after either: no smoking, smoking a denicotinized cigarette, or smoking a low-nicotine cigarette. Analysis of this PET data revealed that smoking a denicotinized and a low-nicotine cigarette resulted in 26% and 79% alpha4beta2* nAChR occupancies, respectively, across three regions of interest. The EC50 determined from this dataset was 0.75 ng/ml. Given the consistency of findings between our previous study with regular cigarettes and the present study, nicotine inhalation during smoking appears to be solely responsible for alpha4beta2* nAChR occupancy, with other factors (if present at all) having either short-lived or very minor effects. Furthermore, smoking a denicotinized cigarette resulted in substantial nAChR occupancy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706128      PMCID: PMC2773668          DOI: 10.1017/S146114570800922X

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  36 in total

Review 1.  Drugs of abuse and the brain.

Authors:  A I Leshner; G F Koob
Journal:  Proc Assoc Am Physicians       Date:  1999 Mar-Apr

2.  Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review.

Authors:  R West; S Shiffman
Journal:  Psychopharmacology (Berl)       Date:  2001-05       Impact factor: 4.530

3.  In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET.

Authors:  Jean-Dominique Gallezot; Michel Bottlaender; Marie-Claude Grégoire; Dimitri Roumenov; Jean-Robert Deverre; Christine Coulon; Michèle Ottaviani; Frédéric Dollé; André Syrota; Héric Valette
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

4.  Treating smokers before the quit date: can nicotine patches and denicotinized cigarettes reduce cravings?

Authors:  Hamed Rezaishiraz; Andrew Hyland; Martin C Mahoney; Richard J O'Connor; K Michael Cummings
Journal:  Nicotine Tob Res       Date:  2007-11       Impact factor: 4.244

5.  Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380.

Authors:  Alane S Kimes; Svetlana I Chefer; John A Matochik; Carlo S Contoreggi; D Bruce Vaupel; Elliot A Stein; Alexey G Mukhin
Journal:  Neuroimage       Date:  2007-09-19       Impact factor: 6.556

6.  Transdermal nicotine facilitates smoking cessation.

Authors:  J E Rose; E D Levin; F M Behm; C Adivi; C Schur
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

7.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

8.  Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment.

Authors:  K O Fagerström
Journal:  Addict Behav       Date:  1978       Impact factor: 3.913

9.  2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling.

Authors:  A O Koren; A G Horti; A G Mukhin; D Gündisch; A S Kimes; R F Dannals; E D London
Journal:  J Med Chem       Date:  1998-09-10       Impact factor: 7.446

10.  Nicotine blood levels and subjective craving for cigarettes.

Authors:  M E Jarvik; D C Madsen; R E Olmstead; P N Iwamoto-Schaap; J L Elins; N L Benowitz
Journal:  Pharmacol Biochem Behav       Date:  2000-07       Impact factor: 3.533

View more
  58 in total

1.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

2.  Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Arthur L Brody
Journal:  Curr Med Imaging Rev       Date:  2011-05-01

3.  Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Authors:  Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

Review 4.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

5.  Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 Positron Emission Tomography Study.

Authors:  Arthur L Brody; Robert Hubert; Ryutaro Enoki; Lizette Y Garcia; Michael S Mamoun; Kyoji Okita; Edythe D London; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern
Journal:  Neuropsychopharmacology       Date:  2017-03-06       Impact factor: 7.853

Review 6.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

7.  Understanding of nicotinic acetylcholine receptors.

Authors:  Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

8.  Cortical activity differs during nicotine deprivation versus satiation in heavy smokers.

Authors:  David E Evans; Steven K Sutton; Jason A Oliver; David J Drobes
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

9.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

10.  Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine.

Authors:  Eric C Donny; Melissa Jones
Journal:  Drug Alcohol Depend       Date:  2009-05-15       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.